Abstract
Many efforts are currently being made to connect small molecules to target proteins by extracting pharmacological data from bibliographic sources and storing them in annotated chemical libraries. Here, small molecules are further connected to biological pathways, with particular focus to pathways involving members of the nuclear receptor family. The results bring to light the relative importance for molecules on gaining selectivity at the target level, when the target has an intrinsic promiscuity at the pathway level, and highlight the implications for drug discovery to address current challenges related to poor drug efficacy and toxicity. Details on the main limitations encountered during the molecule-to-target-to-pathway annotation process are also discussed.
Keywords: Wnt signaling pathway, retinoic X receptor, farnesoid X receptor, lipid metabolism, CYP7A1 inhibition
Current Topics in Medicinal Chemistry
Title: Connecting Small Molecules to Nuclear Receptor Pathways
Volume: 7 Issue: 15
Author(s): Kristina Hettne, Montserrat Cases, Scott Boyer and Jordi Mestres
Affiliation:
Keywords: Wnt signaling pathway, retinoic X receptor, farnesoid X receptor, lipid metabolism, CYP7A1 inhibition
Abstract: Many efforts are currently being made to connect small molecules to target proteins by extracting pharmacological data from bibliographic sources and storing them in annotated chemical libraries. Here, small molecules are further connected to biological pathways, with particular focus to pathways involving members of the nuclear receptor family. The results bring to light the relative importance for molecules on gaining selectivity at the target level, when the target has an intrinsic promiscuity at the pathway level, and highlight the implications for drug discovery to address current challenges related to poor drug efficacy and toxicity. Details on the main limitations encountered during the molecule-to-target-to-pathway annotation process are also discussed.
Export Options
About this article
Cite this article as:
Hettne Kristina, Cases Montserrat, Boyer Scott and Mestres Jordi, Connecting Small Molecules to Nuclear Receptor Pathways, Current Topics in Medicinal Chemistry 2007; 7 (15) . https://dx.doi.org/10.2174/156802607782194671
DOI https://dx.doi.org/10.2174/156802607782194671 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Amyotrophic Lateral Sclerosis: A Genetic Point of View
Current Molecular Medicine The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Acetylenic Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Current Drug Targets for Thymic Neoplasms
Current Cancer Drug Targets Hck Inhibitors as Potential Therapeutic Agents in Cancer and HIV Infection
Current Medicinal Chemistry The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Kefir: A Synbiotic with Approved Anticarcinogenic Properties
Current Bioactive Compounds MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Current Cancer Drug Targets Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews